FDA Veers From Guidance In Some Supplement Health Claim Decisions – Court
This article was originally published in The Tan Sheet
FDA made unreasonable demands with disclaimers for proposed qualified health claims for vitamin C and vitamin E to reduce the risk of cancer, according to a court ruling.
You may also be interested in...
FDA can set somewhat vague standards for dietary supplement firms' compliance with some good manufacturing practice regulations, according to a ruling in a complaint challenging the agency's authority to issue GMP requirements.
FDA says in a final guidance that observational studies alone are insufficient support for health claims, but the agency also says it is interested in making it easier for those studies to support claims
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.